About BVF Partners
BVF Partners is a private equity firm founded in 1993. It is primarily based in San Francisco, United States. In the last 12 months, it has participated in 9 funding rounds.
Overall BVF Partners portfolio has seen 43 IPOs and 22 acquisitions, namely X4 Pharmaceuticals, SpringWorks Therapeutics and Blueprint Medicines. A lot of funds co-invest with BVF Partners, with names like Janus Henderson Investors sharing a substantial percentage of its portfolio.
BVF Partners has a team of 9 people, including 2 partners.
Key Metrics
BVF Partners' Portfolio
They have invested in a total of 96 companies. Their most recent investment was in Ambrosia Biosciences (Series B round) on Mar 31, 2026. Here is the most recent investment by BVF Partners:Date | Company | Round | Amount | Co-Investors |
|---|---|---|---|---|
Mar 31, 2026 | Series B | 6478 | ||
Mar 18, 2026 | Series B | 8395 | ||
Feb 13, 2026 | Post IPO | 5718 | ||
Feb 05, 2026 | Series D | 8952 |
Here is the portfolio snapshot of BVF Partners:
Investments by Year
The maximum number of investments were made in 2024
Team profile of BVF Partners
BVF Partners has a team of 9 members including 2 Partners and 2 Principals located in United States. BVF Partners' team does not sit on the board of any company as of now.Here is a list of all team members in BVF Partners:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | San Francisco | - | ||
Partner | San Francisco | - | ||
Principal | San Francisco | - | ||
Principal | California | - | ||
Advisor | San Francisco | - | ||
Analyst | San Francisco | - | ||
Analyst | United States | - | - | |
Analyst | New Haven | - |
Co-investors of BVF Partners
Over the past 33 years, 219 investors have co-invested in BVF Partners's portfolio companies.
- Top Co-investors of BVF Partners: 219 investors entered a company along with BVF Partners. These include investors like Janus Henderson Investors (23 companies).
BVF Partners News
•
Entera Bio Announces Pricing of $10.0 Million Direct Investment Bakersfield•Apr 02, 2026•Entera Bio, BVF Partners
•
Colorado biotech Ambrosia lands $100M for oral GLP-1Endpoints•Mar 31, 2026•Ambrosia Biosciences, Blue Owl, Deep Track Capital, Samsara BioCapital and 8 others
•
Briggs Morrison's Crossbow Unveils $77M Series B for T Cell EngagersEndpoints•Mar 18, 2026•Crossbow, Arkin, MPM BioImpact, LifeLink Ventures and 11 others
•
•
Immunic Announces Oversubscribed Private Placement of up to USD 400 MillionPR Newswire•Feb 13, 2026•Immunic, BVF Partners, Immunic, B. Riley Securities
•
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct FinancingGlobeNewswire•Jan 14, 2026•Foghorn Therapeutics, BVF Partners
•
Diagonal Therapeutics Announces $125 Million Series B FinancingBenzinga•Jan 08, 2026•Diagonal Therapeutics, Sanofi Ventures, Janus Henderson Investors, RV Invest and 13 others
•
Bambusa Therapeutics Completes Series A-2 Financing to Boost Bispecific ProgramsPR Newswire•Nov 17, 2025•RA Capital Management, , Bambusa Therapeutics, Salvia and 7 others
•
Repare Therapeutics Agrees To Acquisition Citing Best Path For Stakeholder ValueBenzinga•Nov 17, 2025•Repare Therapeutics, XenoTherapeutics, Blue Owl, Orbimed and 1 other
•
Expedition Therapeutics Raises $165 Million in Series A Funding for COPD InhibitorBusiness Wire•Oct 09, 2025•Expedition Therapeutics, Novo Holdings, Sofinnova Investments, Adage Capital Management and 8 others
